Caris Life Sciences Reports Tomorrow After Watching Its Stock Lose Half Its Value Since Launch

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

CAI reports after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price action shows CAI typically experiences significant volatility around earnings, with an average absolute Day 0 move of 6.28% and Day +1 move of 8.68%. The Day +1 range averages 17.04%, indicating substantial intraday swings as investors digest results.

The three most recent earnings events show mixed directional patterns but consistent volatility. The February 2026 report saw a 5.08% Day 0 gain followed by a 4.68% Day +1 gain, reflecting positive momentum. However, the November 2025 report triggered a sharp -6.32% Day 0 decline that accelerated to -15.75% by Day +1, demonstrating how negative surprises can compound. The August 2025 report produced a 7.45% Day 0 gain and 5.61% Day +1 gain, though with a wide 20.89% Day +1 range.

Investors should prepare for meaningful price movement, with historical data suggesting moves in the 6-9% range are typical, though individual events have produced swings exceeding 15%.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 3.70% (±$0.60) through the August 21 expiration, which is notably lower than CAI's average historical Day 0 move of 6.28% and substantially below the average Day +1 move of 8.68%. This suggests options traders may be underpricing potential volatility, or alternatively, that recent earnings volatility has been anomalous and the market expects a more muted reaction this quarter.

Part 3: What Analysts Are Saying

Analyst sentiment on Caris Life Sciences remains overwhelmingly bullish despite recent stock price weakness. The consensus rating stands at 4.43 out of 5.0, with 10 Strong Buy ratings, 0 Moderate Buys, 4 Holds, and no Sell ratings among the 14 analysts covering the stock. This represents one of the most concentrated bullish views in the healthcare technology sector.

The average price target of $27.00 implies 67.7% upside from the current price of $16.10, with estimates ranging from a low of $21.00 (30.4% upside) to a high of $36.00 (123.6% upside). This wide range reflects differing views on the company's growth trajectory and path to sustained profitability, though even the most conservative target suggests meaningful appreciation potential.

Analyst sentiment has remained unchanged over the past month, indicating conviction in the bullish thesis despite the stock's technical deterioration. The stability of ratings suggests analysts view current price levels as a buying opportunity rather than a reason to reassess their outlook. The consensus appears anchored in CAI's long-term potential in precision medicine and molecular profiling, with analysts looking past near-term volatility to focus on the company's expanding market opportunity and improving unit economics.

Part 4: Technical Picture

Caris Life Sciences enters earnings with a sharply deteriorating technical picture. The Barchart Technical Opinion currently registers 100% Sell, intensifying from 100% Sell last week and 56% Sell a month ago. This acceleration in negative momentum reflects growing technical pressure as the stock has failed to hold key support levels.

Timeframe Analysis:

• Short-term (100% Sell): Strong sell signal indicates immediate-term momentum is decisively negative heading into the earnings event
• Medium-term (100% Sell): Sell signal confirms weakness extends beyond near-term fluctuations into the intermediate trend
• Long-term (100% Sell): Sell signal across the longer timeframe suggests the overall trend structure has broken down

Trend Characteristics: The trend exhibits Good strength with Average direction, indicating the selling pressure is well-defined but not yet reaching extreme levels that might suggest capitulation.

The stock is trading at $16.10, positioned below its 20-day ($16.27), 50-day ($16.90), 100-day ($17.64), and 200-day ($21.50) moving averages, though it remains above its 5-day ($15.95) and 10-day ($15.75) averages. This configuration shows a stock in a sustained downtrend with only the shortest-term averages providing support. The 25% gap between the current price and the 200-day moving average is particularly concerning, indicating significant technical damage.

Key resistance now sits at the 20-day moving average of $16.27, which the stock is testing from below. A strong earnings beat would need to propel CAI above this level and ideally reclaim the 50-day average at $16.90 to signal a potential trend reversal. Support appears at the recent lows near $15.50, aligning with the lower bound of the options expected move. The overall technical setup is cautionary, with the stock entering earnings from a position of weakness rather than strength. The uniformly bearish signals across all timeframes suggest any positive earnings surprise will face resistance from overhead supply, while a disappointment could accelerate the existing downtrend toward the $15.00 psychological level.